MA50517A - Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole - Google Patents

Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole

Info

Publication number
MA50517A
MA50517A MA050517A MA50517A MA50517A MA 50517 A MA50517 A MA 50517A MA 050517 A MA050517 A MA 050517A MA 50517 A MA50517 A MA 50517A MA 50517 A MA50517 A MA 50517A
Authority
MA
Morocco
Prior art keywords
preparation process
intermediate preparation
derivative intermediate
methoxypyrrole derivative
methoxypyrrole
Prior art date
Application number
MA050517A
Other languages
English (en)
Inventor
Deok Ki Eom
Chun Ho Lee
Jeong-Taek Shin
Jeong Hyun Son
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of MA50517A publication Critical patent/MA50517A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050517A 2017-05-31 2018-05-31 Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole MA50517A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170067646A KR102233456B1 (ko) 2017-05-31 2017-05-31 4-메톡시피롤 유도체의 중간체 제조 방법

Publications (1)

Publication Number Publication Date
MA50517A true MA50517A (fr) 2020-09-09

Family

ID=64456008

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050517A MA50517A (fr) 2017-05-31 2018-05-31 Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole

Country Status (23)

Country Link
US (1) US10710961B2 (fr)
EP (2) EP3630722A4 (fr)
JP (1) JP6799177B2 (fr)
KR (1) KR102233456B1 (fr)
CN (1) CN110637009B (fr)
AU (1) AU2018278731B2 (fr)
BR (1) BR112019024976A2 (fr)
CA (1) CA3061708C (fr)
CL (1) CL2019003449A1 (fr)
CO (1) CO2019012686A2 (fr)
DO (1) DOP2019000292A (fr)
EC (1) ECSP19081839A (fr)
JO (1) JOP20190264A1 (fr)
MA (1) MA50517A (fr)
MX (1) MX2019014323A (fr)
MY (1) MY193162A (fr)
NZ (1) NZ758743A (fr)
PE (1) PE20200399A1 (fr)
PH (1) PH12019502638A1 (fr)
RU (1) RU2718920C1 (fr)
SA (1) SA519410408B1 (fr)
TN (1) TN2019000300A1 (fr)
WO (1) WO2018221971A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN112094219B (zh) * 2020-09-10 2022-08-05 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
WO2022051979A1 (fr) * 2020-09-10 2022-03-17 广东莱佛士制药技术有限公司 Procédé de préparation d'intermédiaire de bloqueur compétitif d'ions de potassium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
KR100286874B1 (ko) 1998-03-04 2001-04-16 성재갑 보호된 4-아미노메틸-피롤리딘-3-온의 제조방법
BRPI0514925A (pt) 2004-09-03 2008-07-01 Yuhan Corp derivados de pirrol[2,3-c]piridina e processos para a preparação destes
EP2336107B1 (fr) 2004-09-30 2015-09-23 Takeda Pharmaceutical Company Limited Inhibiteurs de pompe a protons
DE102004053191A1 (de) 2004-11-04 2006-05-11 Bayer Cropscience Ag 2,6-Diethyl-4-methyl-phenyl substituierte Tetramsäure-Derivate
CA2631880C (fr) 2005-12-19 2011-03-29 Pfizer Inc. Benzimidazoles substitues par des chromanes et leur utilisation en tant qu'inhibiteurs de la pompe a protons
BR112015010908A2 (pt) * 2012-11-19 2017-07-11 Jiangsu Hansoh Pharmaceutical Co Ltd derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형

Also Published As

Publication number Publication date
JOP20190264A1 (ar) 2019-11-12
JP6799177B2 (ja) 2020-12-09
EP3630722A1 (fr) 2020-04-08
PH12019502638A1 (en) 2020-07-13
MX2019014323A (es) 2020-02-10
SA519410408B1 (ar) 2021-10-21
RU2718920C1 (ru) 2020-04-15
CN110637009B (zh) 2023-11-10
CL2019003449A1 (es) 2020-03-27
CA3061708A1 (fr) 2018-12-06
AU2018278731B2 (en) 2021-02-18
CN110637009A (zh) 2019-12-31
NZ758743A (en) 2022-07-29
BR112019024976A2 (pt) 2020-06-23
PE20200399A1 (es) 2020-02-26
CA3061708C (fr) 2021-06-22
AU2018278731A1 (en) 2019-11-21
US10710961B2 (en) 2020-07-14
TN2019000300A1 (en) 2021-05-07
WO2018221971A1 (fr) 2018-12-06
KR102233456B1 (ko) 2021-03-29
US20200181079A1 (en) 2020-06-11
CO2019012686A2 (es) 2020-04-01
KR20180131081A (ko) 2018-12-10
MY193162A (en) 2022-09-26
EP4219448A1 (fr) 2023-08-02
EP3630722A4 (fr) 2020-10-21
JP2020518647A (ja) 2020-06-25
DOP2019000292A (es) 2019-12-15
ECSP19081839A (es) 2019-11-30

Similar Documents

Publication Publication Date Title
MA49472A (fr) Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole
ES2981118T3 (es) Producción de lípidos
MA50517A (fr) Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole
MA54253A (fr) Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines
MA52906A (fr) Procédé de préparation d'amg 416
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
MA48723A (fr) Procédé de production d'anticorps multispécifiques
DK3635101T3 (da) Manipulerede ligasevarianter
MA48798A (fr) Procédé de production d'ozanimod
MA52795A (fr) Dérivé de carbamoylpyridone polycyclique
MA52802A (fr) Dérivé de pyridone polycyclique
MA50169A (fr) Procédé de production d'un électrocatalyseur
MA42423A (fr) Procédé de préparation d'un revêtement
MA50796A (fr) Procédé de décomposition de phosphogypse
IL260465B (en) A process for preparing an antibody-rifamycin conjugate
IL267508B (en) A process for the preparation of 2-pyridylethyl carboxamide derivatives
MA54396A (fr) Procédé de préparation de n-phénylpyrazole-1-carboxamides
FR3038312B1 (fr) Procede de preparation de polyols
MA41790A (fr) Dérivé de morphinane
FR3048968B1 (fr) Procede de preparation d'alkylamines
MA42264A (fr) Procédé de préparation d'oltipraz
MA49555A (fr) Procédé amélioré de préparation d'imetelstat
DK3512518T3 (da) Buprenophinformuleringer med langvarig frigivelse
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
FR3049599B1 (fr) Procede de preparation de l'hexafluorobutadiene.